Afficher la notice abrégée

dc.rights.licenseopenen_US
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorSCHOLLHAMMER, Romain
dc.contributor.authorQUINTYN RANTY, Marie-Laure
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorDE CLERMONT-GALLERANDE, Henri
dc.contributor.authorCAVELIER, Florine
dc.contributor.authorVALVERDE, Ibai E
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorVIMONT, Delphine
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorHINDIE, Elif
hal.structure.identifierInstitut de Neurosciences cognitives et intégratives d'Aquitaine [INCIA]
dc.contributor.authorMORGAT, Clement
dc.date.accessioned2023-06-28T08:11:46Z
dc.date.available2023-06-28T08:11:46Z
dc.date.issued2023-04-18
dc.identifier.issn2072-6694en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/182850
dc.description.abstractEnThe imaging of Prostate-Specific Membrane Antigen (PSMA) is now widely used at the initial staging of prostate cancers in patients with a high metastatic risk. However, its ability to detect low-grade tumor lesions is not optimal. First, we prospectively performed neurotensin receptor-1 (NTS) IHC in a series of patients receiving both [Ga]Ga-PSMA-617 and [Ga]Ga-RM2 before prostatectomy. In this series, PSMA and GRP-R IHC were also available (n = 16). Next, we aimed at confirming the PSMA/GRP-R/NTS expression profile by retrospective autoradiography (n = 46) using a specific radiopharmaceuticals study and also aimed to decipher the expression of less-investigated targets such as NTS, SST and CXCR4. In the IHC study, all samples with negative PSMA staining (two patients with ISUP 2 and one with ISUP 3) were strongly positive for NTS staining. No samples were negative for all three stains-for PSMA, GRP-R or NTS. In the autoradiography study, binding of [In]In-PSMA-617 was high in all ISUP groups. However, some samples did not bind or bound weakly to [In]In-PSMA-617 (9%). In these cases, binding of [n]In-JMV 6659 and [In]In-JMV 7488 towards NTS and NTS was high. Targeting PSMA and NTS/NTS could allow for the detection of all intraprostatic lesions.
dc.language.isoENen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subject.enProstate cancer
dc.subject.enNeuropeptide
dc.subject.enPSMA
dc.subject.enGRP-R
dc.subject.enNTS1
dc.subject.enNTS2
dc.subject.enNeurotensin
dc.title.enTheranostics of Primary Prostate Cancer: Beyond PSMA and GRP-R
dc.title.alternativeCancers (Basel)en_US
dc.typeArticle de revueen_US
dc.identifier.doi10.3390/cancers15082345en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed37190273en_US
bordeaux.journalCancersen_US
bordeaux.volume15en_US
bordeaux.hal.laboratoriesInstitut de neurosciences cognitives et intégratives d'Aquitaine (INCIA) - UMR 5287en_US
bordeaux.issue8en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionCNRSen_US
bordeaux.teamImagerie multimodale translationnelle
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
bordeaux.import.sourcepubmed
hal.exportfalse
workflow.import.sourcepubmed
dc.rights.ccCC BYen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cancers&rft.date=2023-04-18&rft.volume=15&rft.issue=8&rft.eissn=2072-6694&rft.issn=2072-6694&rft.au=SCHOLLHAMMER,%20Romain&QUINTYN%20RANTY,%20Marie-Laure&DE%20CLERMONT-GALLERANDE,%20Henri&CAVELIER,%20Florine&VALVERDE,%20Ibai%20E&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Thumbnail

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée